Pneumococcal colonization among tracheostomy tube dependent children

Guliz Erdem 1*, Anirudh K. Singh 2, Anthony J. Brusnahan 2, Amber N. Moore 2, William J. Barson 1, Amy Leber 3, Jorge E. Vidal 4, Serkan Atici 5, Samantha J. King 1,2*

1 College of Medicine, The Ohio State University, and Nationwide Children’s Hospital, Columbus, Ohio, United States of America, 2 Center for Microbial Pathogenesis, Nationwide Children’s Hospital, Columbus, Ohio, United States of America, 3 Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio, United States of America, 4 Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America, 5 Department of Pediatrics, Marmara University School of Medicine, Istanbul, Turkey

* samantha.king@nationwidechildrens.org (SJK); guliz.erdem@nationwidechildrens.org (GE)

Abstract

Streptococcus pneumoniae colonization is a precursor to pneumococcal disease. Although children with a tracheostomy have an increased risk of pneumococcal pneumonia, the pneumococci colonizing their lower airways remain largely uncharacterized. We sought to compare lower respiratory tract isolates colonizing tracheostomy patients and a convenience sample of isolates from individuals intubated for acute conditions. We collected pneumococcal isolates from the lower respiratory tract of 27 patients with a tracheostomy and 42 patients intubated for acute conditions. We compared the penicillin susceptibility, rates of co-colonization, genetic background, and serotype of isolates colonizing these patient populations. Isolates from both groups showed high genetic diversity. Forty multi-locus sequence types and 20 serotypes were identified. There was no significant difference in serotype distribution, co-colonization rates, vaccine coverage, or non-susceptibility to penicillin among pneumococcal isolates from the two groups. Colonization of the lower airways with non-vaccine serotypes 15B/C, 23B and 35B was noted for the first time in patients with tracheostomies and supports recently observed increases in nasopharyngeal colonization and disease due to these serotypes.

Introduction

Asymptomatic colonization of the nasopharynx is considered a precursor for clinical pneumococcal disease. Levels of colonization are higher in children than adults and certain groups of patients could be at increased risk of developing pneumococcal infection [1–3]. Patients with tracheostomies have pneumococcal colonization of their lower respiratory tract; however, little is known about the strains colonizing these patients [4, 5]. A study published in 1979 examined pneumococcal colonization of 27 children (mean age of 8.5 years) biweekly over a one year period [5]. Pneumococci were isolated from 22.5% of the 444 samples taken; although, 22 of those isolates were from patients with active pneumonia. A more recent study of tracheostomy
patients, both adults and children, at a long-term care facility revealed 17% of cultures were positive for pneumococci [4]. This study also defined the serotypes of endotracheal isolates. They did not differentiate the isolates from adult and pediatric patients, but the serotypes of the isolates were 23F, 19F, 17F, 15A, 6A and some non-typeable.

*Streptococcus pneumoniae* is a diverse species, as demonstrated by the >90 serotypes [6]. While the 7-valent conjugate vaccine (PCV7) reduced invasive disease and colonization by vaccine types, some other serotypes increased in prevalence [7, 8]. Introduction of PCV13 further reduced pneumococcal disease, but recent reports indicate similar increases in colonization and disease due to some non-vaccine serotypes [9, 10, 11].

Although strains have different propensities to cause disease, studying strains colonizing patients with underlying conditions may identify pneumococcal lineages likely to cause disease. Isolates colonizing paediatric patients with tracheostomies have rarely been evaluated. Thus, we compared the serotypes, susceptibility to penicillin, and genetic background of pneumococci colonizing the lower respiratory tract of children with tracheostomies and a convenience sample of children intubated due to acute non-pneumococcal illness.

**Materials and methods**

Medical records at Nationwide Children’s Hospital, Columbus, Ohio from January 2013 to December 2014 were reviewed following Institutional Review Board (IRB) approval (IRB16-00812). Given that the study was reviewed as Risk Level 1, no greater than minimal risk, and involved retrospective chart review, the IRB waived the requirement for informed consent. We identified tracheostomy patients from which a pneumococcal isolate was recovered from deep tracheal aspirates. Deep tracheal aspirates were collected by trained medical staff and respiratory therapists, using sterile technique and standard airway precautions, thus minimizing the risk of contamination with upper respiratory tract flora to the extent possible. A single isolate from each patient was used. If the same patient was hospitalized multiple times during the study period, the first pneumococcal isolate obtained was used in the study. No individual had documented pneumococcal disease within the prior year. This resulted in 27 isolates for use in the study. For comparison we used a convenience sample of the 42 isolates from deep tracheal aspirates patients intubated for acute conditions and cultured within 24 hours of admission obtained over the same study period. The majority of patients were children; however, a few older than 18 years of age were also treated at our hospital due to their pre-existing chronic conditions. Whether there were any significant differences between the patient populations were assessed using a two-tailed chi-squared test with Yate’s correction (P ≤ 0.05). The exception was for age, where statistical significance of differences was assessed by a two-tailed Student’s *t* test.

Samples were cultured using conventional media including sheep blood, chocolate and MacConkey agars with and plates incubated at 37˚C in 5% CO2. Pneumococci were identified by optochin susceptibility, latex agglutination or Vitek GP Cards (bioMerieux). Antimicrobial susceptibilities were performed using Etest strips (bioMerieux) with established breakpoints [12]. Isolates were recovered from frozen stocks and grown for DNA preparation using previously described methodology [13]. Multi-locus Sequence Typing (MLST) was used to define the genetic background of isolates (http://pubmlst.org/s_pneumoniae/). Genetic relatedness and clonal complexes, named for the predicted founder, were inferred using goeBURST available in PHYLOViZ 2.0. Novel alleles are available in GenBank (accession numbers MG675061-MG675064) and added to the pneumococcal MLST database.

Sero-types were assigned using multiplex PCR [14]. The serotype of multiplex-negative isolates was determined by the Quellung reaction (Statens Serum Institute). Non-typeable isolates
were screened for genes that replace the capsule locus in some cases, \( \text{pspK} \) [15], \( \text{aliC} \) (\( \text{aliCF AGATGCCAAATGGTTCACGC} \) and \( \text{aliCR GCGCTTTGTTATACCTACCTAGATGT'TTC} \)) and \( \text{aliD} \) [16]. A two-tailed chi-squared test with Yate’s correction was used to identify any significant differences (\( P \leq 0.05 \)) between the two groups of isolates.

**Results**

All tracheostomy patients had underlying conditions associated with respiratory failure requiring chronic ventilation including Trisomy 18, DiGeorge syndrome, muscular dystrophy, traumatic injuries with spinal cord transaction, severe cerebral palsy, congenital tracheal abnormalities and cystic lymphangiomas (S1 Table). The convenience sample included 15 previously healthy children admitted due to viral bronchiolitis, burns, acute onset seizures, drowning or complications during elective surgical procedures including tonsillectomy and ear ventilation tube placement. Nineteen patients had chronic conditions that included cerebral palsy, chronic seizure disorders, hypoxic ischemic encephalopathy, congenital hydronephrosis, obstructive sleep apnea, cartilage hair dysplasia, bronchiectasis, laryngeal cleft, chromosomal abnormalities, eosinophilic esophagitis, heart transplant, brain stem glioma, Stevens Johnson syndrome, pulmonary nodules and asthma (S2 Table). These patients did not have tracheostomy tubes. In addition, eight children had tracheomalacia/laryngomalacia, cough and prematurity.

Due to the retrospective nature of the study the vaccination status of some children is unknown; however, of the children old enough to be vaccinated against pneumococcus 77.7% of the tracheostomy group and 89.5% of the convenience sample were reported as such (Table 1 and S1 and S2 Tables). The median age of the patients was lower in the convenience sample (2 years, interquartile range 0.9–7) compared with the tracheostomy group (5 years, interquartile range 2–9). One of the patients in the tracheostomy group and three of the patients in the control group were immunocompromised (S1 and S2 Tables). There were no statistically significant differences between the patient population in vaccination status, age, sex, immune status, recent antibiotic use and hospitalization (Table 1).

Co-isolation of other potentially pathogenic bacterial species was not significantly different between the groups (63.0% of tracheostomy vs 42.9% of convenience sample isolates \( P = 0.17 \)) (Tables 2 and 3). Viruses detected are reported (S1 and S2 Tables), but as it is difficult in many cases to be certain whether these viruses are the cause of the encounter diagnosis or co-colonizing we did not compare the rates between groups. All immunocompromised patients were co-colonized! with other bacterial species (S1 and S2 Tables). The distribution of non-susceptibility to penicillin was not significantly different between the groups (resistant and intermediate, 33.3% of tracheostomy vs 38.1% of convenience sample isolates, \( P = 0.88 \)).

| Table 1. Patient characteristics. |
|----------------------------------|
| **Tracheostomy tube patients (n = 27)** | **Convenience sample (n = 42)** | **P value\(^{2}\)** |
| Median Age (interquartile range) | 5 (2–9) | 2 (0.9–7) | 0.99 |
| Male | 14 (51.9%) | 29 (69.0%) | 0.24 |
| Immunocompromised | 1 (3.7%) | 3 (7.1%) | 0.95 |
| Antibiotic use last 2 weeks | 1 (3.7%) | 1 (2.4%) | 0.75 |
| Hospitalization | 15 (55.6%) | 26 (61.9%) | 0.78 |
| Reported pneumococcal vaccination | 21 (77.7%) | 34\(^{1}\) (86.8%) | 0.37 |

\(^{1}\) N = 38 as we excluded 4 patients under 2 months as it is below the recommended age for pneumococcal vaccination.

\(^{2}\) Calculated by chi-squared with Yate’s correction with the exception of age for which the means were compared using a two-tailed Student’s \( t \) test.

https://doi.org/10.1371/journal.pone.0206305.t001
### Table 2. Details of pneumococcal isolates.

| Isolate | Serotype | Sequence Type | Clonal Complex | Penicillin MIC | Bacterial Co-colonization |
|---------|----------|---------------|----------------|---------------|---------------------------|
| **Isolates from tracheostomy tube patients** | | | | | |
| 1       | 19F      | 654           | CC654          | 0.03          | -                         |
| 2       | 35B      | 1204          | CC558          | 0.5(I)        | M.c                       |
| 3       | 11A/D    | 62            | CC63           | 0.01          | E., S.a., S.m.            |
| 4       | 21       | 432           | CC432          | 0.01          | P.a.                      |
| 5       | 15 B/C   | 1757          | CC199          | 0.01          | K.p., S.a., S.m.          |
| 6       | 28A      | 546           | CC546          | 0.09          | P.a., S.a.                |
| 7       | 15 B/C   | 199           | CC199          | 0.04          | -                         |
| 8       | 22F/A    | 433           | CC433          | 0.01          | M.c., P.a.                |
| 9       | 21       | 432           | CC432          | 0.02          | H.i., MRSA                |
| 10      | 35B      | 558           | CC558          | 0.75(I)       | -                         |
| 11      | 15 B/C   | 199           | CC199          | <0.01         | M.c.                      |
| 12      | 15 B/C   | **11360**     | CC1262         | 0.04          | C., P.a.                  |
| 13      | 23B      | 439           | CC439          | 0.04          | -                         |
| 14      | 11A/D    | 62            | CC63           | 0.03          | E., H.i.                  |
| 15      | 23A      | **12425**     | CC156          | 0.25(I)       | P.a., S.                  |
| 16      | 10A      | 816           | CC460          | 0.03          | -                         |
| 17      | NT¹      | 2315          | CC2315         | 0.19(I)       | -                         |
| 18      | 15A/F    | 63            | CC63           | 0.25(I)       | A. M.c., P., P.a., S.d.   |
| 19      | 9V/A     | **13967**     | CC15           | 0.04          | P.a., S.                  |
| 20      | 35B      | 558           | CC558          | 1.5(I)        | P.a.                      |
| 21      | 23B      | 1373          | CC156          | 0.09          | -                         |
| 22      | 19F      | 1203          | CC346          | 2(R)          | -                         |
| 23      | 35B      | 3632          | CC558          | 1.5(I)        | E., M.c.                  |
| 24      | 22F/A    | 7314          | CC433          | 0.04          | -                         |
| 25      | 35B      | 558           | CC558          | 0.38(I)       | K.p., S.                  |
| 26      | 6C/D     | 8446          | CC156          | 0.04          | MSSA                      |
| 27      | 19F      | 425           | CC395          | 0.03          | -                         |
| **Convenience sample** | | | | | |
| 1       | 11A/D    | 62            | CC63           | 0.12(I)       | -                         |
| 2       | 11A/D    | 62            | CC63           | 0.01          | -                         |
| 3       | 35B      | 10493         | CC558          | 2(R)          | -                         |
| 4       | 6C/D     | 473           | CC473          | 0.04          | -                         |
| 5       | 15 B/C   | 199           | CC199          | 0.02          | M.c.                      |
| 6       | 35F/47F  | 1635          | CC460          | 0.06          | -                         |
| 7       | 19F      | 320           | CC320          | 4(R)          | -                         |
| 8       | 15 B/C   | **12061**     | CC156          | 0.5(I)        | -                         |
| 9       | 3        | 13499         | CC180          | 0.03          | -                         |
| 10      | 19F      | 654           | CC654          | 0.12(I)       | P.a., R.                  |
| 11      | 19F      | 654           | CC654          | 0.06          | MSSA                      |
| 12      | 15 B/C   | 3280          | CC156          | 0.19(I)       | M.c.                      |
| 13      | 6C/D     | 473           | CC473          | 0.03          | -                         |
| 14      | 3        | 13499         | CC180          | 0.06          | -                         |
| 15      | 19A      | 1451          | CC320          | 4(R)          | M.c.                      |
| 16      | 15 B/C   | 199           | CC199          | 0.04          | M.c.                      |
| 17      | 19A      | 8748          | CC156          | 0.09          | M.c., MSSA                |
| 18      | 23B      | 439           | CC439          | 0.03          | -                         |

(Continued)
Table 2. (Continued)

| Isolate | Serotype | Sequence Type | Clonal Complex | Penicillin MIC | Bacterial Co-colonization |
|---------|----------|---------------|----------------|----------------|--------------------------|
| 19      | 16F      | 659           | CC659/965      | 0.03           | -                        |
| 20      | 11A/D    | 62            | CC63           | 0.04           | -                        |
| 21      | 22F/A    | 433           | CC433          | 0.04           | -                        |
| 22      | 19F      | 654           | CC654          | 0.04           | H.i., M.c.               |
| 23      | 6C/D     | 11413         | CC1390         | 0.04           | N.m., MSSA.              |
| 24      | 16F      | 10439         | CC383          | 0.04           | -                        |
| 25      | 38/25F/25A | 393       | CC393          | 0.04           | H.i.                     |
| 26      | 23F      | 36            | CC439          | 0.06           | M.c.                     |
| 27      | 11A/D    | 62            | CC63           | 0.03           | -                        |
| 28      | 23B      | 1373          | CC156          | 0.12(I)        | MSSA                     |
| 29      | 16F      | 659           | CC659/965      | 0.01           | -                        |
| 30      | 6C/D     | 1379          | CC1379         | 0.38(I)        | H.i.                     |
| 31      | 21       | 432           | CC432          | 0.04           | -                        |
| 32      | NT       | 13966         | CC15           | 0.25(I)        | -                        |
| 33      | 23B      | 439           | CC439          | 0.04           | H.i.                     |
| 34      | 6C/D     | 473           | CC473          | 0.5(I)         | M.c.                     |
| 35      | 11A/D    | 62            | CC63           | 0.04           | MSSA                     |
| 36      | 35B      | 558           | CC558          | 1.5(I)         | -                        |
| 37      | 19A      | 1451          | CC320          | 3(R)           | -                        |
| 38      | 22F/A    | 433           | CC433          | 0.06           | M.c.                     |
| 39      | 23B      | 1451          | CC156          | 0.5(I)         | H.i. MSSA                |
| 40      | 23A      | 338           | CC156          | 0.19(I)        | -                        |
| 41      | 23A      | 338           | CC156          | 0.04           | -                        |

1 NT cspA and pspK negative and aliD and aliC positive.
2 cspA, pspK, aliC and aliD negative confirmed by quelling.
3 Bold text indicates sequence types novel to this study.
4 Defined as a group of STs where each strain is a single locus variant of at least one other strain in the group.
5 Minimum inhibitory concentration; I indicates intermediate levels of penicillin susceptibility and R non-susceptibility to penicillin (9). All other strains are susceptible to penicillin.
6 Abbreviations for co-colonizing bacterial species: A., Acinetobacter of unspecified species; C. Corynebacterium of unspecified species; E., Enterobacter of unspecified species; H.i., Haemophilius influenzae; K.p., Klebsiella pneumonia; MRSA, methicillin resistant Staphylococcus aureus; M.c., Moraxella catarrhalis; N.m., Neisseria meningitidis; P., Proteus of unspecified species; Ps., Pseudomonas of unspecified species; P.a., Pseudomonas aeruginosa; R., Rothia of unspecified species; S., Serratia of unspecified species; S.a., Staphylococcus aureus; S.m., Stenotrophomanas maltophilia; Group G Streptococcus.

Table 3. Data summary.

|                      | Strains from tracheostomy tube patients | Strains from convenience sample | P value1 |
|----------------------|----------------------------------------|---------------------------------|----------|
| Bacterial co-colonization | 63.0%                                  | 42.9%                           | 0.17     |
| Non-susceptibility to penicillin | 33.3%                                  | 38.1%                           | 0.88     |
| PCV13 coverage        | 14.8%                                  | 26.2%                           | 0.41     |
| Serotypes reported increased post PCV13 (23B, 15 B/C, 35B) | 40.7%                                  | 21.4%                           | 0.15     |

1 Calculated by chi-squared with Yate’s correction.
MLST demonstrated high diversity, but did not support a clonal lineage for strains colonizing children with a tracheostomy. Only 13 of the 40 STs identified represented multiple isolates and six were new STs. The most common STs were ST62 (N = 7), ST199 (N = 4), ST558 (N = 4) and ST654 (N = 4). The 40 STs were members of 23 clonal complexes. The most common of which, CC156 (N = 10), CC63 (N = 8) CC558 (N = 7) and CC199 (N = 5), represented both patient populations.

The 69 strains included 20 serogroups/serotypes. Most of the frequently identified serotypes were common in both groups. The majority of isolates were serotypes not included in PCV13 (85.2% of tracheostomy vs 73.8% of convenience sample isolates, P = 0.41). Although pneumococcal vaccination was not specifically documented, the majority of patients were reported as appropriately vaccinated (77.7% of tracheostomy vs 89.5% of convenience sample P = 0.37). One isolate from each group was non-typeable. One these isolates encoded AliC and AliD [16]; while no alternative capsular locus genes were identified in the other.

Discussion

We observed no differences in rates of co-colonization with other potentially pathogenic bacteria between the two groups. We don’t believe this was influenced by the distribution of immunocompromised patients. As only 3.7% of the tracheostomy patients and 7.1% of the convenience sample were immunocompromised. A wide range of different co-colonizing bacteria were observed. As co-colonization rates with any specific species or genus were low it was not possible to investigate differences in distribution of individual species between the tracheostomy and control groups.
We observed no significant differences between the isolates from tracheostomy patients and the convenience sample for susceptibility to penicillin or vaccine coverage (Table 3). This observation is important as no studies following introduction of PCV13 have studied pneumococci colonizing the lower airway of pediatric tracheostomy patients. In fact, there have been very few studies of pneumococcal colonization of pediatric patients with a tracheostomy tube. We cannot compare our study with that of Brook et al. 1979 as our study was aimed at examining the isolates from tracheostomy patients and not the rates of colonization [5]. The study by Adler et al. 2012 identified the serotype of isolates; however, they did not differentiate the isolates from adult and pediatric patients [4]. The serotypes of the 45 isolates from the trachea or trachea and nasopharynx were 23F, 19F, 17F, 15A, 6A and non-typeable. The limited numbers of serotypes in this study are likely for two reasons. Firstly, patients were sampled between one and three times and it is not clear how many of the isolates were from the same patients and therefore potentially the result of the same colonization event. Secondly, strains were likely spread between patients at this long-term care facility. In contrast, patients included in our study were only at Nationwide Children’s for relatively short periods of time prior to sampling. Variation in the serotype distribution as compared to those in our study may reflect differences in vaccination status, which is not discussed, or geographical and temporal patterns of colonization [4].

As colonization precedes disease, the serotypes observed can predict those likely to be increasingly observed in disease. Colonization of the lower airways with the non-vaccine serotypes 15B/C, 23B and 35B was noted for the first time. Previous studies have reported post-PCV13 increases in colonization due to non-vaccine serotypes including 23B, 15B/C and 35B [9, 17, 18]. Our data suggest higher numbers of these serotypes in the tracheostomy patients; although the difference is not significant with the available sample size (40.7% vs 21.4%, Fig 1, P = 0.15).

The increase in colonization and disease due to 35B has been attributed to increased presence of ST588 [10, 18]. Our data also suggest that there is an increase in isolation of single locus variants of ST588 post-PCV13. A previous study suggested ST199 that expressed the 19A capsule and was prevalent in the PCV7 era is now associated with serogroup 15 [10]. Our isolates included four ST199 isolates all of which were 15B/C. The pathogenic potential of these isolates is not known, but these data suggest there should be further monitoring of the distribution of these isolates in colonization and disease.

The retrospective nature of the study leads to some limitations including the lack of nasopharyngeal samples, the fact that strains were only isolated at a single time point and that for some patients we did not have confirmed vaccination records. However, this work adds to the current understanding of pneumococci colonizing the airway of children with a tracheostomy. The number of children with a tracheostomy, while increasing, is relatively small and it is possible some of the differences observed in this study would be statistically significant if there were a larger sample size. Despite this, colonization of the lower airways with non-vaccine serotypes 15B/C, 23B and 35B was noted for the first time in patients with tracheostomies and supports recently observed increases in nasopharyngeal colonization and disease due to these serotypes.

**Supporting information**

S1 Table. Clinical information for the patients with a tracheostomy.
(DOCX)

S2 Table. Clinical information for the convenience sample.
(DOCX)
Acknowledgments

We thank Melissa Moore-Clingenpeel of the Biostatistics Shared Resource at Nationwide Children’s Hospital for help with the statistical analysis. Authors also thank Dr. Fumori Sakai and Renzo Valeriani, from Emory University Rollins School of Public Health for their assistance with some serotyping assays. When partially completed this study was presented as a poster at Infectious Disease Week, New Orleans, 28 October 2016.

Author Contributions

Conceptualization: Guliz Erdem, Anirudh K. Singh, William J. Barson, Samantha J. King.

Formal analysis: Guliz Erdem, Anirudh K. Singh, Samantha J. King.

Funding acquisition: Guliz Erdem, Samantha J. King.

Investigation: Guliz Erdem, Anirudh K. Singh, Anthony J. Brusnahan, Amber N. Moore, Jorge E. Vidal, Serkan Atici, Samantha J. King.

Methodology: Guliz Erdem, Anirudh K. Singh, Amy Leber, Jorge E. Vidal, Samantha J. King.

Project administration: Samantha J. King.

Resources: Amy Leber.

Supervision: Anirudh K. Singh, Jorge E. Vidal, Samantha J. King.

Validation: Anirudh K. Singh.

Writing – original draft: Guliz Erdem, Samantha J. King.

Writing – review & editing: Guliz Erdem, Anirudh K. Singh, Anthony J. Brusnahan, Amber N. Moore, William J. Barson, Amy Leber, Jorge E. Vidal, Serkan Atici, Samantha J. King.

References

1. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med. 2009; 30(2):189–209. Epub 2009/03/20. https://doi.org/10.1055/s-0029-1202938 PMID: 19296419.

2. van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65(1):17–24. https://doi.org/10.1016/j.jinf.2012.02.017 PMID: 22394683.

3. Burman LA, Norrby R, Trolltor B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis. 1985; 7(2):133–42. PMID: 3890093.

4. Adler A, Ben-David D, Schwaber MJ, Masarwa S, Schwartz D, Porat N, et al. Prevalence of Streptococcus pneumoniae in respiratory samples from patients with tracheostomy in a long-term-care facility. J Clin Microbiol. 2012; 50(10):3368–70. https://doi.org/10.1128/JCM.00763-12 PMID: 22837316.

5. Brook I. Bacterial colonization, tracheobronchitis, and pneumonia following tracheostomy and long-term intubation in pediatric patients. Chest. 1979; 76(4):420–4. Epub 1979/10/01. PMID: 477429.

6. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015; 28(3):871–99. https://doi.org/10.1128/CMR.00024-15 PMID: 2608553.

7. O’Brien KL, Millar EV, Zell ER, Bronson M, Weatherholtz R, Reid R, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007; 196(8):1211–20. https://doi.org/10.1086/521833 PMID: 17955440.

8. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013; 10(9):e1001517. https://doi.org/10.1371/journal.pmed.1001517 PMID: 24086113.
9. Lee GM, Kleinman K, Pelton S, Lipsitch M, Huang SS, Lakoma M, et al. Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period. Pediatrics. 2017; 140(5). https://doi.org/10.1542/peds.2017-0001 PMID: 28978716.

10. Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006–2015. Pediatr Infect Dis J. 2016; 35(8):901–6. https://doi.org/10.1097/INF.0000000000001206 PMID: 27420806.

11. Olarte L, Kaplan SL, Barson WJ, Romero JR, Lin PL, Tan TQ, et al. Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States. J Clin Microbiol. 2017; 55(3):724–34. https://doi.org/10.1128/JCM.01778-16 PMID: 27847379.

12. Institute CaLS. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement. 2014.

13. Whatmore AM, Barcus VA, Dowson CG. Genetic diversity of the streptococcal competence (com) gene locus. J Bacteriol. 1999; 181(10):3144–54. PMID: 10322016.

14. Menezes AP, Reis JN, Ternes YM, Andrade AL, Pimenta FC, Carvalho Mda G, et al. Update of pneumococcal PCR serotyping assay for detection of a commonly occurring type 19F wzy variant in Brazil. J Clin Microbiol. 2013; 51(7):2470–1. https://doi.org/10.1128/JCM.00743-13 PMID: 23658255.

15. Park IH, Kim KH, Andrade AL, Briles DE, McDaniel LS, Nahm MH. Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio. 2012; 3(3). Epub 2012/04/26. https://doi.org/10.1128/mBio.00035-12 PMID: 22532557.

16. Hathaway LJ, Stutzmann Meier P, Battig P, Aebi S, Muhlemann K. A homologue of aliB is found in the capsule region of nonencapsulated Streptococcus pneumoniae. J Bacteriol. 2004; 186(12):3721–9. Epub 2004/06/04. https://doi.org/10.1128/JB.186.12.3721-3729.2004 PMID: 15175285.

17. Weinberger R, von Kries R, van der Linden M, Rieck T, Siedler A, Falkenhorst G. Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine. 2018; 36(4):572–7. https://doi.org/10.1016/j.vaccine.2017.11.085 PMID: 29258705.

18. Chochua S, Metcalf BJ, Li Z, Walker H, Tran T, McGee L, et al. Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015–2016. Emerg Infect Dis. 2017; 23(6):922–30. https://doi.org/10.3201/eid2306.170071 PMID: 28516866.